AI assistant
FendX Technologies — Regulatory Filings 2023
Apr 14, 2023
48310_rns_2023-04-13_ed2e8a33-3d05-41ee-87f3-51532e0ae213.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
FORM 51‐102F3
MATERIAL CHANGE REPORT
Item 1.
Name and Address of Company
FendX Technologies Inc. (the “ Company ”) 2010 Winston Park Dr., 2nd Floor Oakville, ON L6H 5R7
Item 2.
Date of Material Change
April 12, 2023
Item 3. News Release
The News Release dated April 13, 2023 was disseminated by Newsfile Corp. on April 13, 2023.
Item 4. Summary of Material Change
The Company announced its participation in the Bloom Burton & Co. Healthcare Investor Conference. On April 25, 2023 Dr. Carolyn Myers, President and Chief Executive Officer of FendX will participate in the Bloom Burton & Co. Healthcare Investor Conference to meet with investors attending the conference. The conference hosts Canada’s premier publicly traded and venture‐backed private companies as well as the most promising pre‐venture companies in the healthcare industry.
The Company announced it entered into an investor relations agreement dated April 12, 2023 with Medical Gold Limited Liability Company (LLC) (“ Medical Gold ”), pursuant to which Medical Gold agreed to provide market awareness and investor communications services to the Company in exchange for an aggregate amount of US$25,000, payable upon signing. The services will include news dissemination on MedicalGold.ca and other social media, creation of CEO interviews and website sponsorship on MedicalGold.ca. The term of the Agreement is for a period of 12 months ending on April 11, 2024. Medical Gold and its principals are at arm’s length to the Issuer. Medical Gold’s contact information is as follows: 416 SW 1st Avenue, Fort Lauderdale, Florida 33301, attention: Robert Sinn, email [email protected], telephone: 813‐385‐6487.
Item 5. Full Description of Material Change
5.1 Full Description of Material Change
The material change is fully described in Item 4 above and in the News Release attached hereto.
5.2 Disclosure for Restructuring Transactions
Not Applicable.
Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51‐102
Not Applicable.
Item 7. Omitted Information
None.
Item 8. Executive Officer
Please contact Carolyn Myers, Director, Chief Executive Officer, at 1‐800‐344‐9868.
Item 9. Date of Report
April 13, 2023